Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, April 18, 2018
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway
Wednesday, April 11, 2018
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab
Friday, March 30, 2018
Nanobiotix 2017 Annual Results
Monday, January 22, 2018
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting
Thursday, January 11, 2018
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers
Tuesday, December 26, 2017
Nanobiotix: 2017 review and 2018 expected milestones
FDA approves Nanobiotix's first Immuno-Oncology trial
Monday, November 13, 2017
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting
Friday, November 10, 2017
Nanobiotix provides update on the global development of its lead product NBTXR3
Monday, October 23, 2017
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: